Fangzhou Shares Rise After Launching Novo Nordisk Weight-Loss Drug

Shares of Fangzhou Inc., an online chronic disease management company in China, rose sharply on Monday following its announcement of the launch of Novo Nordisk’s Kyinsu drug on its internet platform. The stock climbed 4.9% to close at HK$0.85 on the news.

Partnership Expansion

The company stated that offering the popular weight-loss and diabetes treatment represents a further expansion of its collaboration with Danish pharmaceutical giant Novo Nordisk. Fangzhou highlighted that China is expected to be a major market for Kyinsu, positioning the company to capitalize on strong demand.

Fangzhou operates primarily through online retail pharmacy services and comprehensive medical services. The addition of a high-profile drug like Kyinsu strengthens its platform's offerings for chronic disease management.

Financial and Market Context

Ad

The stock's move occurred within a specific technical and fundamental context that may have amplified investor interest. The broader Hong Kong market provided a positive backdrop, with the Hang Seng index gaining 1.8% during the session.

Key points for Fangzhou's stock include:

• Technical Positioning: The shares are trading significantly below their 52-week high of HK$5.26 and just above the 52-week low of HK$0.65.
• Recent Funding: Earlier in 2026, Fangzhou raised HK$144.3 million to accelerate the expansion of its AI-driven chronic disease platform.
• Profitability Outlook: The company had previously signaled a potential return to profitability based on strong platform growth, which may be attracting buyers at its currently depressed valuation.